Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07444632) titled 'Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies' on Feb. 26.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: M.D. Anderson Cancer Center
Condition:
Lymphoid
Hodgkin Lymphoma
Intervention:
Drug: Rituximab
Drug: Fludarabine
Drug: TGFBR2 KO CAR27/IL-15 NK cells
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: August 31, 2026
Target Sample S...